Angelalign Technology (FRA:77D) EBIT: €28.8 Mil (TTM As of Dec. 2025)


FRA:77D Angelalign Technology Inc FRA:77D
69 GF Score
Price €8.15
GF Value €11.62
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Angelalign Technology EBIT?

Angelalign Technology FRA:77D 69 EBIT is €28.8 Mil as of Dec. 2025. GuruFocus rates FRA:77D with a GF Score™ of 69/100 and a GF Value™ of €11.62 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Angelalign Technology's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €14.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €28.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Angelalign Technology's annualized ROC % for the quarter that ended in Dec. 2025 was 8.14%. Angelalign Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 32.05%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Angelalign Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 2.62%.

Angelalign Technology  (FRA:77D) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Angelalign Technology's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=34.012 * ( 1 - 26.82% )/( (314.896 + 297.012)/ 2 )
=24.8899816/305.954
=8.14 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=676.662 - 51.694 - ( 422.701 - max(0, 174.322 - 484.394+422.701))
=314.896

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=652.836 - 71.696 - ( 366.052 - max(0, 143.578 - 427.706+366.052))
=297.012

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Angelalign Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=28.918/( ( (86.503 + max(-46.683, 0)) + (93.972 + max(-81.457, 0)) )/ 2 )
=28.918/( ( 86.503 + 93.972 )/ 2 )
=28.918/90.2375
=32.05 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(28.597 + 14.942 + 11.517) - (51.694 + 0 + 50.045)
=-46.683

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(25.859 + 14.498 + 15.889) - (71.696 + 0 + 66.007)
=-81.457

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Angelalign Technology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=28.768/1099.468
=2.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Angelalign Technology EBIT Related Terms

Angelalign Technology EBIT Historical Data

* Premium members only.

The historical data trend for Angelalign Technology's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Angelalign Technology EBIT Chart

Angelalign Technology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 46.28 34.68 8.92 12.62 28.55

Angelalign Technology Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.30 3.15 9.38 14.31 14.46

FRA:77D vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Angelalign Technology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Angelalign Technology EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Angelalign Technology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Angelalign Technology's EV-to-EBIT falls into.


FRA:77D
69GF Score
Angelalign Technology Inc FRA:77D
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Angelalign Technology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €28.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €28.8 Mil mean?
Angelalign Technology (FRA:77D) has a EBIT of €28.8 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Angelalign Technology.
Is Angelalign Technology's EBIT too high?
Angelalign Technology's current EBIT is €28.8 Mil. Overall, Angelalign Technology has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Angelalign Technology's EBIT compare to ISRG and BDX?
Angelalign Technology's EBIT of €28.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Angelalign Technology. Angelalign Technology's current EBIT is €28.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Angelalign Technology stock overvalued right now?
Based on GuruFocus' analysis, Angelalign Technology (FRA:77D) is currently considered Significantly Undervalued. The stock's GF Value™ is €11.62, compared to a current price of €8.15 — trading 29.9% below its estimated fair value. The current EBIT is €28.8 Mil. Angelalign Technology's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Angelalign Technology (FRA:77D), the current EBIT is €28.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Angelalign Technology (FRA:77D) Overvalued in 2026?

Based on GuruFocus' analysis, Angelalign Technology stock appears to be undervalued. The current stock price of €8.15 is trading 29.9% below its estimated GF Value™ of €11.62. GuruFocus considers Angelalign Technology to be Significantly Undervalued.

Key valuation signals for FRA:77D:

  • EBIT: €28.8 Mil
  • GF Value™: €11.62 vs. price of €8.15 (29.9% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the FRA:77D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Angelalign Technology Business Description

Other Exchanges AGLFF:USA06699:Hong Kong
Address No. 500 Zhengli Road, 6th Floor - 7th Floor, Building No. 7, KIC Business Center, Yangpu District, Shanghai, CHN
Angelalign Technology Inc is an investment holding company. It is principally engaged in clear aligner treatment solutions, including treatment planning services, manufacturing, and marketing of clear aligners. The company provides dental professionals with self-developed digital orthodontic solutions. The company's Angelalign clear aligner system facilitates dental professionals throughout the entire clear aligner treatment process, including digitally-assisted case assessment support and treatment planning services, provide dental professionals with digitally-assisted case assessment support and treatment planning services, and helps dental professionals design, review, and modify treatment plans.
69GF Score

Get the complete analysis for FRA:77D

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.15
Price
€11.62
GF Value